Iclusig, Leukemia Drug, Probed By FDA After Reports Of Serious Adverse Events
Ariad's shares fell 7 percent in early trade on Friday. Postmarket reports show that Iclusig patients experienced heart attacks
iclusig leukemia drug probed fda report adverse events ariad share fall percent early trade friday postmarket report iclusig patient experience heart attack